KOD Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 0.91%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Kodiak Sciences, Inc. has a consensus price target of $35.50, signalling upside risk potential of 40.43%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.12%. Given that Kodiak Sciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Amicus Therapeutics, Inc..

Kodiak Sciences, Inc. has a beta of 2.640, which suggesting that the stock is 164.038% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 6.99x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -82.06%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Kodiak Sciences, Inc. has a consensus price target of $35.50, signalling upside risk potential of 40.43%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.63 which suggests that it could grow by 10.19%. Given that Kodiak Sciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Kodiak Sciences, Inc. has a beta of 2.640, which suggesting that the stock is 164.038% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 14.16x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nuvalent, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of --. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Nuvalent, Inc.'s return on equity of -38.24%.

Kodiak Sciences, Inc. has a consensus price target of $35.50, signalling upside risk potential of 40.43%. On the other hand Nuvalent, Inc. has an analysts' consensus of $142.65 which suggests that it could grow by 41.94%. Given that Nuvalent, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Nuvalent, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.640, which suggesting that the stock is 164.038% more volatile than S&P 500. In comparison Nuvalent, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Nuvalent, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Nuvalent, Inc. quarterly revenues of --. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Nuvalent, Inc.'s net income of -$122.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Nuvalent, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus -- for Nuvalent, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Processa Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of --. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Processa Pharmaceuticals, Inc.'s return on equity of -309.65%.

Kodiak Sciences, Inc. has a consensus price target of $35.50, signalling upside risk potential of 40.43%. On the other hand Processa Pharmaceuticals, Inc. has an analysts' consensus of $1.00 which suggests that it could grow by 1090.48%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.640, which suggesting that the stock is 164.038% more volatile than S&P 500. In comparison Processa Pharmaceuticals, Inc. has a beta of 1.140, suggesting its more volatile than the S&P 500 by 13.98%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Processa Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Processa Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Processa Pharmaceuticals, Inc. quarterly revenues of --. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Processa Pharmaceuticals, Inc.'s net income of -$3.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Processa Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus -- for Processa Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.